The drug, Remdesivir, is slowly gaining the importance of the world in its fight against Covid19 pandemic.
It is widely considered to be a front-runner among the investigational therapies being tested as treatments for COVID-19. which has sickened more than three million people and killed at least 217,000. There are no proven treatments or vaccines..
A top U.S. health official said Gilead Sciences Inc's antiviral drug remdesivir is likely to become the standard of care for COVID-19 after early results from a clinical trial showed it helped certain patients recover more quickly.
Only one negative report came from China that explained the therapy with Remdesivir did not lead to clinical improvement in patients in China.
But in US, experimental drug remdesivir met the main goal in a closely watched government-funded clinical trial treating hospitalized COVID-19 patients.
After the positive results, shares of the company which manufacture Remdesivir, Gilead GILD, +6.40% were up 7.6% in trading on Wednesday.
Gilead said in a statement on Wednesday that remdesivir met the study’s primary endpoint, and the federal agency is expected to provide additional information about that trial. The primary outcome in this trial is recovery by 29 days of treatment, according to the study’s listing on ClinicalTrials.gov.
Analysts said that while the data is promising, additional details are needed to better determine remdesivir’s efficacy. “It seems like remdesivir is active and has a favorable impact in COVID-19,” Mizuho Securities analyst Salim Syed wrote in an investor note.
Gilead also said a company-sponsored open-label Phase 3 trial testing the therapy in 6,000 severely ill patients found that those taking a 5-day or 10-day course of treatment led to similar results. At least 52% of participants taking either dosing regimen were discharged from the hospital after 14 days of treatment, and at least 53% of those patients were reported as reaching “clinical recovery.”